Chronic treatment with rivastigmine in patients with Alzheimer鈥檚 disease: A study on primary motor cortex excitability tested by 5 Hz-repetitive transcranial magnetic stimulation

详细信息	查看全文 | 推荐本文 |

• 作者：A. Trebbastoni^a ; F. Gilio^b ; F. D&rsquo ; Antonio^a ; C. Cambieri^a ; M. Ceccanti^a ; C. de Lena^a ; M. Inghilleri^a ; ^{maurizio.inghilleri@uniroma1.it}
• 关键词：Alzheimer&rsquo ; s disease (AD) ; Synaptic plasticity ; Repetitive transcranial magnetic stimulation (rTMS) ; Cholinesterase inhibitor
• 刊名：Clinical Neurophysiology
• 出版年：2012
• 期刊代码：61_13882457
• 类别：med
• 出版时间：May, 2012
• 卷：123
• 期：5
• 页码：902-909
• 文件大小：322 K

摘要

Objective

To investigate changes in cortical excitability and short-term synaptic plasticity we delivered 5 Hz repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex in 11 patients with mild-to-moderate Alzheimer鈥檚 disease (AD) before and after chronic therapy with rivastigmine.

Methods

Resting motor threshold (RMT), motor evoked potential (MEP), cortical silent period (CSP) after single stimulus and MEP facilitation during rTMS trains were tested three times during treatment. All patients underwent neuropsychological tests before and after receiving rivastigmine. rTMS data in patients were compared with those from age-matched healthy controls.

Results

At baseline, RMT was significantly lower in patients than in controls whereas CSP duration and single MEP amplitude were similar in both groups. In patients, rTMS failed to induce the normal MEP facilitation during the trains. Chronic rivastigmine intake significantly increased MEP amplitude after a single stimulus, whereas it left the other neurophysiological variables studied unchanged. No significant correlation was found between patients鈥?neuropsychological test scores and TMS measures.

Conclusions

Chronic treatment with rivastigmine has no influence on altered cortical excitability and short-term synaptic plasticity as tested by 5 Hz-rTMS.

Significance

The limited clinical benefits related to cholinesterase inhibitor therapy in patients with AD depend on factors other than improved plasticity within the cortical glutamatergic circuits.